|Year : 2020 | Volume
| Issue : 3 | Page : 223
Fibrinous uveitis after transscleral diode cyclophotocoagulation
Vijayalakshmi A Senthilkumar
Department of Glaucoma, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Madurai, Tamil Nadu, India
|Date of Submission||29-Mar-2020|
|Date of Decision||30-Apr-2020|
|Date of Acceptance||01-May-2020|
|Date of Web Publication||14-Sep-2020|
Dr. Vijayalakshmi A Senthilkumar
Department of Glaucoma, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Madurai, Tamil Nadu
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Senthilkumar VA. Fibrinous uveitis after transscleral diode cyclophotocoagulation. TNOA J Ophthalmic Sci Res 2020;58:223
A 52-year-old male diagnosed as advanced primary open angle glaucoma in both eyes, developed uncontrolled intraocular pressure (IOP) despite maximal antiglaucoma medications. His best-corrected visual acuity and IOP were 6/9 and 6/6 and 46 and 22 mmHg in the right eye (RE) and the left eye (LE), respectively. We performed transscleral diode laser cyclophotocoagulation (TSCPC, Oculight SL × 810 nm, G-probe: Iridex Corporation, Mountain View, CA, USA) in the RE. Postoperatively, he was treated with steroid eye-drops and cycloplegics. Ten days later, he presented with severe pain and redness in the RE. Anterior-segment evaluation of the RE revealed severe fibrinous uveitis [Figure 1]. TSCPC first performed by Beckman, traditionally used only in eyes with end-stage glaucoma with little or no visual potential, has now become a popular minimally invasive treatment for glaucoma with good vision., As it is a cyclodestructive procedure, considerable posttreatment anterior uveitis is an anticipated sequela and may be minimized with preoperative use of anti-inflammatory therapy, especially in patients with good visual potential.
|Figure 1: (a and b, magnified) Slit lamp photography showing circumcorneal congestion with extensive fibrinous reaction in the anterior chamber|
Click here to view
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Beckman H, Kinoshita A, Rota AN, Sugar HS. Transscleral ruby laser irradiation of the ciliary body in the treatment of intractable glaucoma. Trans Am Acad Ophthalmol Otolaryngol 1972;76:423-36.
Egbert PR, Fiadoyor S, Budenz DL, Dadzie P, Byrd S. Diode laser transscleral cyclophotocoagulation as a primary surgical treatment for primary open-angle glaucoma. Arch Ophthalmol 2001;119:345-50.
Rotchford AP, Jayasawal R, Madhusudhan S, Ho S, King AJ, Vernon SA. Transscleral diode laser cycloablation in patients with good vision. Br J Ophthalmol 2010;94:1180-3.